|
1
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Abdel-Raheem MM, Potti A, Becker WK,
Saberi A, Scilley BS and Mehdi SA: Late adrenal metastasis in
operable non-small-cell lung carcinoma. Am J Clin Oncol. 25:81–83.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
National Lung Screening Trial Research
Team, ; Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD,
Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM and Sicks JD:
Reduced lung-cancer mortality with low-dose computed tomographic
screening. N Engl J Med. 365:395–409. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Spira A and Ettinger DS: Multidisciplinary
management of lung cancer. N Engl J Med. 350:379–392. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li MJ, He Q, Li M, Luo F and Guan YS: Role
of gefitinib in the targeted treatment of non-small-cell lung
cancer in Chinese patients. Onco Targets Ther. 9:1291–1302.
2016.PubMed/NCBI
|
|
7
|
Abdullah MM, Bhat A, Mohamed AK, Ching FY,
Ahmed N and Gantotti S: Gefitinib as first line therapy in
Malaysian patients with mutation-positive non-small-cell lung
cancer: A single-center retrospective study. Oncol Lett.
11:2757–2762. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yu T, Guo Z, Fan H, Song J, Liu Y, Gao Z
and Wang Q: Cancer-associated fibroblasts promote non-small cell
lung cancer cell invasion by upregulation of glucose-regulated
protein 78 (GRP78) expression in an integrated bionic microfluidic
device. Oncotarget. 7:25593–25603. 2016.PubMed/NCBI
|
|
9
|
Bertolini G, D'Amico L, Moro M, Landoni E,
Perego P, Miceli R, Gatti L, Andriani F, Wong D, Caserini R, et al:
: Microenvironment-modulated metastatic
CD133+/CXCR4+/EpCAM-lung cancer-initiating
cells sustain tumor dissemination and correlate with poor
prognosis. Cancer Res. 75:3636–3649. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kurimoto R, Iwasawa S, Ebata T, Ishiwata
T, Sekine I, Tada Y, Tatsumi K, Koide S, Iwama A and Takiguchi Y:
Drug resistance originating from a TGF-β/FGF-2-driven
epithelial-to-mesenchymal transition and its reversion in human
lung adenocarcinoma cell lines harboring an EGFR mutation. Int J
Oncol. 48:1825–1836. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Folco EJ, Rocha VZ, López-Ilasaca M and
Libby P: Adiponectin inhibits pro-inflammatory signaling in human
macrophages independent of interleukin-10. J Biol Chem.
284:25569–25575. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yokota T, Oritani K, Takahashi I, Ishikawa
J, Matsuyama A, Ouchi N, Kihara S, Funahashi T, Tenner AJ, Tomiyama
Y and Matsuzawa Y: Adiponectin, a new member of the family of
soluble defense collagens, negatively regulates the growth of
myelomonocytic progenitors and the functions of macrophages. Blood.
96:1723–1732. 2000.PubMed/NCBI
|
|
13
|
Kelesidis I, Kelesidis T and Mantzoros CS:
Adiponectin and cancer: A systematic review. Br J Cancer.
94:1221–1225. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Barb D, Williams CJ, Neuwirth AK and
Mantzoros CS: Adiponectin in relation to malignancies: A review of
existing basic research and clinical evidence. Am J Clin Nutrit. 86
Suppl:S858–S866. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tang CH and Lu ME: Adiponectin increases
motility of human prostate cancer cells via adipoR, p38, AMPK, and
NF-kappaB pathways. Prostate. 69:1781–1789. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Umekawa K, Kimura T, Kudoh S, Suzumura T,
Nagata M, Mitsuoka S, Matsuura K, Oka T, Yoshimura N, Kira Y and
Hirata K: Reaction of plasma adiponectin level in non-small cell
lung cancer patients treated with EGFR-TKIs. Osaka City Med J.
59:53–60. 2013.PubMed/NCBI
|
|
17
|
Vansaun MN: Molecular pathways:
Adiponectin and leptin signaling in cancer. Clin Cancer Res.
19:1926–1932. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Otani K, Kitayama J, Yasuda K, Nio Y,
Iwabu M, Okudaira S, Aoki J, Yamauchi T, Kadowaki T and Nagawa H:
Adiponectin suppresses tumorigenesis in ApcMin/+ mice.
Cancer Lett. 288:177–182. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Soliman PT, Wu D, Tortolero-Luna G,
Schmeler KM, Slomovitz BM, Bray MS, Gershenson DM and Lu KH:
Association between adiponectin, insulin resistance, and
endometrial cancer. Cancer. 106:2376–2381. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ishikawa M, Kitayama J, Kazama S,
Hiramatsu T, Hatano K and Nagawa H: Plasma adiponectin and gastric
cancer. Clin Cancer Res. 11:466–472. 2005.PubMed/NCBI
|
|
21
|
Kim KY, Baek A, Hwang JE, Choi YA, Jeong
J, Lee MS, Cho DH, Lim JS, Kim KI and Yang Y: Adiponectin-activated
AMPK stimulates dephosphorylation of AKT through protein
phosphatase 2A activation. Cancer Res. 69:4018–4026. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Barb D, Neuwirth A, Mantzoros CS and Balk
SP: Adiponectin signals in prostate cancer cells through Akt to
activate the mammalian target of rapamycin pathway. Endocr Relat
Cancer. 14:995–1005. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Landskroner-Eiger S, Qian B, Muise ES,
Nawrocki AR, Berger JP, Fine EJ, Koba W, Deng Y, Pollard JW and
Scherer PE: Proangiogenic contribution of adiponectin toward
mammary tumor growth in vivo. Clin Cancer Res. 15:3265–3276. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Denzel MS, Hebbard LW, Shostak G, Shapiro
L, Cardiff RD and Ranscht B: Adiponectin deficiency limits tumor
vascularization in the MMTV-PyV-mT mouse model of mammary cancer.
Clin Cancer Res. 15:3256–3264. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Holland WL, Miller RA, Wang ZV, Sun K,
Barth BM, Bui HH, Davis KE, Bikman BT, Halberg N, Rutkowski JM, et
al: Receptor-mediated activation of ceramidase activity initiates
the pleiotropic actions of adiponectin. Nat Med. 17:55–63. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ribeiro R, Araújo AP, Coelho A, Catarino
R, Pinto D, Araújo A, Calçada C, Lopes C and Medeiros R: A
functional polymorphism in the promoter region of leptin gene
increases susceptibility for non-small cell lung cancer. Eur J
Cancer. 42:1188–1193. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shih CM, Lee YL, Chiou HL, Chen W, Chang
GC, Chou MC and Lin LY: Association of TNF-alpha polymorphism with
susceptibility to and severity of non-small cell lung cancer. Lung
Cancer. 52:15–20. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cui E, Deng A, Wang X, Wang B, Mao W, Feng
X and Hua F: The role of adiponectin (ADIPOQ) gene polymorphisms in
the susceptibility and prognosis of non-small cell lung cancer.
Biochem Cell Biol. 89:308–313. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gioulbasanis I, Georgoulias P,
Vlachostergios PJ, Baracos V, Ghosh S, Giannousi Z, Papandreou CN,
Mavroudis D and Georgoulias V: Mini nutritional assessment (MNA)
and biochemical markers of cachexia in metastatic lung cancer
patients: Interrelations and associations with prognosis. Lung
Cancer. 74:516–520. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bruera E: ABC of palliative care.
Anorexia, cachexia, and nutrition. BMJ. 315:1219–1222. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Batista ML Jr, Olivan M, Alcantara PS,
Sandoval R, Peres SB, Neves RX, Silverio R, Maximiano LF, Otoch JP
and Seelaender M: Adipose tissue-derived factors as potential
biomarkers in cachectic cancer patients. Cytokine. 61:532–539.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sun Y and Lodish HF: Adiponectin
deficiency promotes tumor growth in mice by reducing macrophage
infiltration. PloS One. 5:e119872010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Peng J, Tsang JY, Ho DH, Zhang R, Xiao H,
Li D, Zhu J, Wang F, Bian Z, Lui VC, et al: Modulatory effects of
adiponectin on the polarization of tumor-associated macrophages.
Int J Cancer. 137:848–858. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tan PH, Tyrrell HE, Gao L, Xu D, Quan J,
Gill D, Rai L, Ding Y, Plant G, Chen Y, et al: Adiponectin receptor
signaling on dendritic cells blunts antitumor immunity. Cancer Res.
74:5711–5722. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shibata S, Tada Y, Hau CS, Mitsui A,
Kamata M, Asano Y, Sugaya M, Kadono T, Masamoto Y, Kurokawa M, et
al: Adiponectin regulates psoriasiform skin inflammation by
suppressing IL-17 production from gammadelta-T cells. Nat Commun.
6:76872015. View Article : Google Scholar : PubMed/NCBI
|
